


## FAK-IN-6

Cat. No.:	HY-150730
CAS No.:	3033299-38-3
Molecular Formula:	C <sub>25</sub> H <sub>31</sub> ClN <sub>5</sub> O <sub>6</sub> PS
Molecular Weight:	596.04
Target:	FAK
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

Description	FAK-IN-6 is a potent FAK inhibitor with an IC <sub>50</sub> value of 1.415 nM. FAK-IN-6 has anti-proliferative activity against certain cancer cell lines. FAK-IN-6 can be used for researching pancreatic cancer <sup>[1]</sup> .								
IC <sub>50</sub> & Target	IC <sub>50</sub> : 1.415 nM (FAK) <sup>[1]</sup>								
In Vitro	<p>FAK-IN-6 (compound 9h) (0-10 μM; 72 h) has anti-proliferative activity against pancreatic cancer cells, lung cancer cells and lymphoma cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td><td>AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02<sup>[1]</sup></td></tr> <tr> <td>Concentration:</td><td>0-10 μM</td></tr> <tr> <td>Incubation Time:</td><td>72 h</td></tr> <tr> <td>Result:</td><td>Exhibited anti-proliferative activity against AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02 with IC<sub>50</sub>s of 0.9886 ± 0.0086 μM, 5.274 ± 0.9312 μM, 2.918 ± 0.0821 μM, 2.315 ± 0.2969 μM, 1.320 ± 0.2973 μM and 1.220 ± 0.2683 μM.</td></tr> </table>	Cell Line:	AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02 <sup>[1]</sup>	Concentration:	0-10 μM	Incubation Time:	72 h	Result:	Exhibited anti-proliferative activity against AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02 with IC <sub>50</sub> s of 0.9886 ± 0.0086 μM, 5.274 ± 0.9312 μM, 2.918 ± 0.0821 μM, 2.315 ± 0.2969 μM, 1.320 ± 0.2973 μM and 1.220 ± 0.2683 μM.
Cell Line:	AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02 <sup>[1]</sup>								
Concentration:	0-10 μM								
Incubation Time:	72 h								
Result:	Exhibited anti-proliferative activity against AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02 with IC <sub>50</sub> s of 0.9886 ± 0.0086 μM, 5.274 ± 0.9312 μM, 2.918 ± 0.0821 μM, 2.315 ± 0.2969 μM, 1.320 ± 0.2973 μM and 1.220 ± 0.2683 μM.								

## REFERENCES

[1]. Zheng X, et al. Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer. Eur J Med Chem. 2022 Jul 19;241:114607.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA